SeekingAlpha · Aug 13, 2026
BrainsWay: Market Saturation And Competition Could Be Issues
BrainsWay (BWAY) Q2: 35% YoY revenue growth and margin gainsâbut valuation looks rich. Click to read my analysis for more about the pros and cons.
NASDAQ · BWAY
BrainsWay Ltd.
Healthcare · Medical - Devices
$14.40
Down-$0.15 (-1.01%)
Updated Aug 28, 2026, 4:16 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 345.63M
- P/E ratio
- 66.66
- Dividend yield
- 0.00%
- 52-week range
- $7.14 – $17.40
- Volume
- 96.59K
- Avg. volume
- 67.63K
Price performance
BWAY price history
1M range · 21 trading sessions · Daily adjusted prices
BWAY closed at $14.40 after 21 trading sessions, down 5.57% for the selected period.
- Last close
- $14.40
- Period change
- -5.57%
- Period low
- $14.19
- Period high
- $16.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $14.61 | $14.61 | $14.15 | $14.40 | 96.59K |
| Aug 26, 2026 | $14.43 | $14.585 | $14.02 | $14.30 | 74.22K |
| Aug 25, 2026 | $14.32 | $14.62 | $14.215 | $14.43 | 56.6K |
| Aug 24, 2026 | $14.53 | $14.53 | $14.10 | $14.19 | 97.71K |
| Aug 21, 2026 | $14.85 | $15.16 | $14.68 | $14.74 | 47.35K |
| Aug 20, 2026 | $15.16 | $15.3263 | $14.835 | $14.97 | 53.7K |
| Aug 19, 2026 | $14.88 | $15.1995 | $14.88 | $15.17 | 71.27K |
| Aug 18, 2026 | $15.35 | $15.35 | $14.52 | $14.66 | 113.12K |
| Aug 17, 2026 | $16.10 | $16.15 | $15.238 | $15.49 | 186.74K |
| Aug 14, 2026 | $16.27 | $16.66 | $15.885 | $16.32 | 120.96K |
| Aug 13, 2026 | $16.67 | $17.29 | $16.315 | $16.47 | 230.24K |
| Aug 12, 2026 | $15.82 | $17.40 | $14.81 | $16.60 | 622.71K |
| Aug 11, 2026 | $15.18 | $15.27 | $14.86 | $14.98 | 119.46K |
| Aug 10, 2026 | $15.28 | $15.4699 | $15.255 | $15.32 | 55.22K |
| Aug 7, 2026 | $15.60 | $16.0398 | $15.37 | $15.50 | 86.72K |
| Aug 6, 2026 | $15.52 | $16.50 | $15.48 | $15.65 | 120.57K |
| Aug 5, 2026 | $15.77 | $15.77 | $14.96 | $15.01 | 83.59K |
| Aug 4, 2026 | $15.84 | $16.15 | $15.37 | $15.80 | 140.95K |
| Aug 3, 2026 | $15.34 | $15.86 | $15.2907 | $15.81 | 86.59K |
| Jul 31, 2026 | $15.71 | $15.72 | $14.82 | $15.23 | 179.58K |
| Jul 30, 2026 | $14.65 | $15.465 | $14.65 | $15.25 | 82.21K |
Latest BWAY news
The latest Smart Investors Daily articles mentioning BWAY.
Stock researchCompany · Overview
BWAY research
Overview
Company profile and research snapshot.
Company profile
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $24.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2020 | Raymond James | Outperform | — |
| Mar 24, 2020 | Cantor Fitzgerald | Overweight | — |
| Mar 24, 2020 | Raymond James | Outperform | — |
| Nov 26, 2019 | Raymond James | Outperform | — |
| May 13, 2019 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Ladenburg Thalmann Maintains Buy on BrainsWay, Raises Price Target to $18.8
Ladenburg Thalmann analyst Jeffrey Cohen maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $18 to $18.8.
SeekingAlpha · Aug 12, 2026
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call August 12, 2026 8:30 AM EDTCompany ParticipantsHadar Levy - Chief Executive OfficerIdo Marom - Chief Financial...
Benzinga · Aug 12, 2026
BTIG Maintains Buy on BrainsWay, Raises Price Target to $20
BTIG analyst Sam Eiber maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $18 to $20.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
